An Incisive, In-depth Analysis on the Vaginitis Treatment Drugs Market
This study offers a comprehensive, 360 degree analysis on the Vaginitis Treatment Drugs market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Vaginitis Treatment Drugs market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Vaginitis Treatment Drugs Market Outlook & Key Findings
- Global vaginitis treatment drugs market expected to grow at over 5% during the forecast period
- Metronidazole, clindamycin, fluconazole, and clotrimazole continue to be the most commonly prescribed drugs for vaginitis treatment
- Holistic emphasis on increasing the cure rates driving R&D efforts for innovative medicines
- Growing recurrence of bacterial vaginosis and complicated vulvovaginal candidiasis (VVC) is a key growth driver
- Bacterial vaginitis recurrence remains a key concern for drug manufacturers
Vaginitis: An Ailment of Complexities
Overgrowth of bacteria (lactobacillus) that reside in vagina disturbs natural balance. Around 33% of women across the US get affected by this extra growth, which further leads to “Vaginititis”.
Vaginitis causes health risks like miscarriages, pre-term births and, above all, 2 to 4 times high risk of getting HIV if left untreated. Chlamydia, gonorrhea, papillomavirus are the other sexually transmitted diseases associated with vaginitis. At times, infertility also sets in.
The above-mentioned factors press the need for treatment of vaginitis. The Vaginitis Treatment Drugs Market encloses OTC medications herein. However, “vaginal bacteria transplants” are the new method of treating vaginitis. As such, the vaginitis treatment drugs market is expected to witness an innovative upswing in the upcoming period.
Nitroimidazole Fostering Extended Inorganic Growth
Nitroimidazole drugs account for over 50% of global vaginitis treatment drugs market. This could be attributed to their availability in an aplomb and they being the widely accepted form of medication for vaginitis.
Tinidazole and Metronidazole are the usually prescribed antibiotic compounds with regards to treatment of vaginitis. Besides, manufacturers have been focusing on introduction of new drugs and collaborations with respect to the same.
For instance - In December 2017, Pfizer Inc. and Basilea Pharmaceutica Ltd. entered into an agreement to develop and commercialize cresemba® (isavuconazole) in China and Asia Pacific region.
On the other hand, recently, Lupin Pharmaceuticals announced an agreement with PlushCare to facilitate bacterial vaginosis (BV) treatment through PlushCare virtual platform.
The basic functionality of PlushCare is enabling patients to book virtual appointment with doctor, discuss the symptoms, and get prescribed for lab testing. These factors are likely to catalyze the vaginitis treatment drugs market as going for medications is turning out to be a step simpler with the above-mentioned measures as well as Rx to OTC conversions.
For instance - in February 2019, Bayer’s Canesten switched from Rx-To-OTC status for vaginal yeast infection treatment in Poland. The other drugs that have switched to OTC mode include clotrimazole, miconazole, and tioconazole. They are used to treat vulvovaginal candidiasis.
Online Pharmacies to take over Conventional Pharmacies During the Forecast Period
Retail pharmacies account for a significant pie of the overall vaginitis treatment drugs sales, with hospital pharmacies, drug stores and mail-order pharmacies contributing towards it.
The Covid-19 crisis has increased drugs sales by mail-order pharmacies and the trend is expected to continue at a significant growth rate in the next few months.
More patients are adopting mail and several online channels to get their prescription drugs. In India alone, 50+ start-ups are operational in the online pharmaceutical landscape.
High Number of Asymptomatic Infections: Key Challenges to Vaginitis Treatment Industry
At least half of the women with bacterial vaginosis (BV) are asymptomatic. Bacterial vaginosis, even when asymptomatic, is related to high incidence of pelvic inflammatory disease and endometritis.
The population with vaginosis is unable to gauge the infection and take early precautions to avoid infection transmission as the asymptomatic nature of vaginosis prevents them. The high number of cases of asymptomatic vaginitis are expected to hamper the demand for antibiotics and antifungal drugs.
In developed countries, awareness campaigns on this count are being conducted which are expected to upscale the market in terms of demand for vaginitis tests and ultimately for vaginitis treatment drugs.
Extensive Research to Drive the Vaginitis Treatment Drugs Market
As per researchers at University of Cape Town, a vaginal health probiotic inclusive of vaginal lactobacillus strains could prove to be a better treatment option for vaginitis.
They further state that risk of sexually transmitted infections and adverse pregnancy outcomes could be lowered by this probiotic.
Research on these grounds is likely to call for more investment in the Vaginitis Treatment Drugs Market in the forecast period.
Vaginitis Treatment Drugs Market: Region-wise Analysis
North America continues to be the most lucrative market for vaginitis treatment drugs. The U. S. holds the largest share of the global vaginitis treatment drugs market due to growing treatment-seeking rate and higher demand for OTC drugs.
Europe’s vaginitis treatment drugs market, which accounts for more than one-fourth of global vaginitis treatment revenues, is also set to witness lucrative growth opportunities in the future as manufacturers are coming up with novel vaginal tablets.
For instance – Gedea has come up with pHyph, a tablet that restores vaginal acidity in the first place.
Outside of these two productive markets, Brazil and South Africa represent significant opportunities for vaginitis treatment drugs market players. TCM (Traditional Chinese Medicine) is being administered for treating vaginitis since the last several years. Research is being conducted for development of more efficient antibiotics as resistance to TCM is springing up.
Leading Players in Vaginitis Treatment Drugs Market
The market for vaginitis treatment remains highly consolidated. The marketplace is witnessing an influx of novel drugs at the global level. With an estimated 25+ vaginitis treatment players, drug developments, clinical trials, and e-commerce, competition is quite fierce. Some of the key players in the Vaginitis Treatment Drugs Market are
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer Inc.
- Mylan N.V.
- Novartis International AG
- Bayer AG
- Sanofi S.A.
- Dr. Reddy's Laboratories Ltd
- Cipla Ltd.
- Sun Pharmaceutical Industries Limited
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report
Vaginitis Treatment Drugs Market: The Way Forward
Vaginitis treatment drugs market outlook remains positive, with FMI’s analysis estimating revenues to grow at over 5.1% consistently. The global outbreak of Covid-19 has created a major overhaul in sales of vaginitis treatment drug in 2020 due to ease in online procurement.
Vaginitis treatment manufacturers are focusing on the introduction of non-antibiotic drugs for the long term treatment of vaginitis as it is witnessing a higher recurrence rate.
Key players are introducing single-dose drugs and over-the-counter drugs which will provide for cost-effective treatment. Moreover, manufacturers are focusing on drug development alliance for expansion of more effective pipeline candidate.
A recent market study published by Future Market Insights (FMI) on the Vaginitis Treatment Drugs Market including global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the Vaginitis Treatment Drugs Market, growth prospects are obtained with maximum precision.
Vaginitis Treatment Drugs Market: Segmentation
The global vaginitis treatment is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
|
Drug Type |
|
|
Indication |
|
|
Route of Administration |
|
|
Route of Administration |
|
|
Schedule of Drug |
|
|
Distribution Channel |
|
|
Regions |
|
Report Chapters
Chapter 01 – Executive Summary
The report initiates with the executive summary of the Vaginitis Treatment Drugs Market , which includes a summary of key findings and statistics of the market. It also includes market size and revenue distribution of market segment of the Vaginitis Treatment Drugs Market .
Chapter 02 – Market Overview
Readers can find the definition and a detailed segmentation of the Vaginitis Treatment Drugs Market in this chapter, which will help them understand the basic information about the market.
Chapter 03 – Key Market Trends
This section includes key product development trend and innovative market expansion strategies.
Chapter 04 – Market Context
This section includes premium insights such as regulatory scenario, epidemiology analysis, pipeline analysis, reimbursement scenario and many more. This section helps readers understand the key factors associated with the Vaginitis Treatment Drugs Market .
Chapter 05 – Market Background
This chapter explains the key macroeconomic factors, drivers, restraints, trends and opportunity analysis that are expected to influence growth of the Vaginitis Treatment Drugs Market over the forecast period. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section. This chapter also covered the COVID19 Crisis impact analysis on vaginitis treatment drugs sales.
Chapter 06 –Global Vaginitis Treatment Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020–2030
This section explains the global market value analysis and forecast for the vaginitis treatment during the forecast period. This chapter includes a detailed analysis of the historical Vaginitis Treatment Drugs Market , along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2020–2030).
Chapter 07 – Global Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Drug Type
Based on drug type, the Vaginitis Treatment Drugs Market is segmented nitroimidazole compound, lincosamide antibiotics, triazoles and imidazoles. In this chapter, readers can find information about the key trends and developments in vaginitis treatment and market attractiveness analysis based on drug type.
Chapter 08 – Global Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Indication
This chapter provides details about the vaginitis treatment based on indication, and has been classified into bacterial vaginitis, fungal vaginitis (yeast infection) and trichomoniasis. In this chapter, readers can understand the market attractiveness analysis based on indication.
Chapter 09 – Global Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Route of Administration
This chapter provides details about the Vaginitis Treatment Drugs Market based on route of administration, and has been classified into oral, cutaneous and vaginal. In this chapter, readers can understand the market attractiveness analysis based on route of administration.
Chapter 10 – Global Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Schedule of Drug
This chapter provides details about the Vaginitis Treatment Drugs Market based on schedule of drug, and has been classified into prescription drugs (Rx) and over-the-counter drugs (OTC). In this chapter, readers can understand the market attractiveness analysis based on schedule of drug.
Chapter 11 – Global Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Distribution Channel
This chapter provides details about the vaginitis treatment based on distribution channel, and has been classified into hospital pharmacies, retail pharmacies, drug stores, and mail order pharmacies. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.
Chapter 12 – Global Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Region
This chapter explains how the Vaginitis Treatment Drugs Market will grow across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa (MEA).
Chapter 13 – North America Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter includes a detailed analysis of growth of the North America Vaginitis Treatment Drugs Market , along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, and market growth based on the drug type and countries in North America.
Chapter 14 – Latin America Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter provides the growth scenario of the Vaginitis Treatment Drugs Market in Latin American countries such as Argentina, Brazil, Mexico, and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.
Chapter 15 –Europe Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter provides the growth scenario of the Vaginitis Treatment Drugs Market in Europe in several countries such as Germany, the U.K., France, Spain, Italy, Russia and the Rest of Europe are included in this chapter.
Chapter 16 – South Asia Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter provides the growth scenario of the Vaginitis Treatment Drugs Market in South Asia in several countries such as India, Thailand, Malaysia, Indonesia, Rest of South Asia are included in this chapter.
Chapter 17 – East Asia Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter highlights the growth of the vaginitis treatment in East Asia by focusing on China, South Korea, and Japan. This section also help readers understand the key factors that are responsible for the growth of the Vaginitis Treatment Drugs Market in East Asia.
Chapter 18 – Oceania Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter highlights the growth of the vaginitis treatment in Oceania. This section also help readers understand the key factors that are responsible for the growth of the Vaginitis Treatment Drugs Market in Australia and New Zealand.
Chapter 19 – Middle East & Africa Vaginitis Treatment Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter provides information about how the Vaginitis Treatment Drugs Market will grow in major countries in the Middle East & Africa region such as GCC Countries, South Africa, Turkey, Northern Africa and the Rest of MEA, during the forecast period.
Chapter 20 – Key and Emerging Countries Vaginitis Treatment Drugs Market Analysis
This chapter provides information about how the Vaginitis Treatment Drugs Market will grow in key and emerging countries such as the U.S., Canada, Germany, U.K, France, Italy, China, India, Japan, South Korea, South Africa, Turkey and other countries during the forecast period.
Chapter 21- Market Structure Analysis
In this chapter, readers can find detailed company share analysis, and tier structure analysis.
Chapter 22 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the Vaginitis Treatment Drugs Market , along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Pfizer Inc., Mylan NV, Novartis AS, Bayer AG and more.
Chapter 23 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the vaginitis treatment report.
Chapter 24 – Research Methodology
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the Vaginitis Treatment Drugs Market .
Sources and Primary Research Splits (%)
|
Industry Interactions |
|
|
References Catalogue |
|
COVID -19 : Impact Analysis
Request the coronavirus impact analysis across industries and markets
Request Covid -19 ImpactGet in touch
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.